Integra LifeSciences (NASDAQ:IART) Releases Earnings Results, Beats Estimates By $0.13 EPS

Integra LifeSciences (NASDAQ:IART) announced its quarterly earnings data on Tuesday. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13, FiscalAI reports. Integra LifeSciences had a positive return on equity of 17.43% and a negative net margin of 30.15%.The firm had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same period last year, the firm earned $0.41 earnings per share. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. Integra LifeSciences updated its FY 2026 guidance to 2.400-2.500 EPS and its Q2 2026 guidance to 0.440-0.520 EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

• Leadership change: Stuart Essig has resumed the CEO role (retaining Chairman) with a long-term commitment and the company added Michael McBreen as Chief Commercial Officer to sharpen commercial execution, culture, and customer focus.
• Q1 beat and updated EPS guide: Q1 revenue was $392M and adjusted EPS $0.54 (above guidance); company maintained 2026 revenue guidance of $1.66B–$1.70B and raised full-year adjusted EPS to $2.40–$2.50, citing tariff benefits and operational improvements.
• Tissue Reconstruction momentum and reimbursement positioning: Tissue Reconstruction grew ~6.4% organic (strong Integra Skin, DermaClose, PriMatrix), and management says ~90% of wound reconstruction revenue is inpatient (not impacted by new CMS outpatient skin substitute rules) with the portfolio priced to compete under the new reimbursement framework.
• Quality, supply and product returns: The Compliance Master Plan remediation is progressing with improving supply reliability and Braintree production expected by end of June, but management says the 2026 guide does not rely on meaningful contribution from products still off-market.
• Cash flow and leverage path: Q1 operating cash flow improved to $9.8M, the company expects ~+$150M in operating cash flow vs. 2025, reports net debt of $1.6B and a 4.1x leverage ratio with a plan to approach target leverage of 2.5x–3.5x by end of 2026.

Integra LifeSciences Trading Down 2.8%

Shares of Integra LifeSciences stock traded down $0.39 during trading on Thursday, reaching $13.61. 715,858 shares of the stock were exchanged, compared to its average volume of 833,038. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66. The stock’s fifty day moving average is $10.16 and its 200 day moving average is $11.72. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -2.11 and a beta of 1.08. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $16.49.

Institutional Trading of Integra LifeSciences

A number of institutional investors have recently modified their holdings of IART. Rubric Capital Management LP boosted its holdings in shares of Integra LifeSciences by 58.4% during the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock worth $90,233,000 after purchasing an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY boosted its holdings in shares of Integra LifeSciences by 57.5% during the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock worth $26,767,000 after purchasing an additional 796,300 shares during the period. Kotler Kevin purchased a new stake in shares of Integra LifeSciences during the fourth quarter worth about $5,309,000. Soleus Capital Management L.P. boosted its holdings in shares of Integra LifeSciences by 29.4% during the second quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company’s stock worth $17,029,000 after purchasing an additional 315,614 shares during the period. Finally, J. Goldman & Co LP lifted its holdings in Integra LifeSciences by 30.8% in the fourth quarter. J. Goldman & Co LP now owns 1,243,772 shares of the life sciences company’s stock worth $15,448,000 after buying an additional 292,961 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IART has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Wells Fargo & Company raised their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday. Truist Financial reduced their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Finally, Citigroup raised their price objective on Integra LifeSciences from $9.00 to $11.00 and gave the company a “sell” rating in a research note on Wednesday. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $15.20.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.